Founders of early-stage start-ups are passionate, driven and optimistic. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong.
How do we ensure that not only the rich benefit from cell and gene therapy? Rob Collison of Cambridge Consultants says: It’s about more than cutting costs
The future promises a digitally connected healthcare system that empowers both patients and carers alike. So, what’s the next step for pharma companies and device developers with ambitions in the space?
The current state of in vitro diagnostics is no longer fit for purpose. Inadequate procedures mean that critical insights are often missed, while expenditure statistics on both sides of the Atlantic reveal lagging levels of investment.
We’re ramping up our commitment to The Engine, the ambitious venture ecosystem spun out of MIT to support ‘Tough Tech’ companies and solve key challenges in climate change, human health and advanced systems.
To decentralise, or not to decentralise, that is the question. This Web3 dilemma reflects the likely thoughts of current digital leaders who want to make the best use of their digital assets while maintaining trust in their data systems.